In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes—the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB)—returning between 28 percent and 36 percent, more than double the S&P 500’s roughly 18 percent. That came after three consecutive years of underperformance. Was biotech’s strong 2025 a fluke or part of a sustained rebound? The Motley Fool shares a few key trends that might offer direction. As biotech

Tag-uri: Coronavirus